News
Monument Therapeutics partners with FNIH to advance MT1988, a promising treatment for cognitive impairment in schizophrenia, ...
The global biotherapeutics company announced that it will seek to streamline operations as part of a broader transformation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback